In Autumn 2020, DOAJ will be relaunching with a new website with updated functionality, improved search, and a simplified application form. More information is available on our blog. Our API is also changing.

Hide this message

Chemorefractory liver metastasis from cervical cancer successfully treated with a combination of yttrium-90 and immunotherapy

Radiology Case Reports. 2020;15(8):1359-1365

 

Journal Homepage

Journal Title: Radiology Case Reports

ISSN: 1930-0433 (Online)

Publisher: Elsevier

Society/Institution: University of Washington

LCC Subject Category: Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine

Country of publisher: United States

Language of fulltext: English

Full-text formats available: PDF, HTML

 

AUTHORS


Michael E. Nance (School of Medicine, University of Missouri, Columbia, MO, USA; Department of Radiology, Section of Vascular and Interventional Radiology, University of Missouri, One Hospital drive, Columbia, MO 65212, USA)

Gregory B. Biedermann, MD (Department of Radiology, Section of Radiation Oncology, University of Missouri, Columbia, Columbia, MO, USA)

Ambarish P. Bhat, MD (Department of Radiology, Section of Vascular and Interventional Radiology, University of Missouri, One Hospital drive, Columbia, MO 65212, USA; Corresponding author.)

Ryan M. Davis, MD (Department of Radiology, Section of Vascular and Interventional Radiology, University of Missouri, One Hospital drive, Columbia, MO 65212, USA)

EDITORIAL INFORMATION

Double blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 8 weeks

 

Abstract | Full Text

Liver metastases in cervical cancer is rare and can be difficult-to-treat. The current guidelines established by the Gynecologic Oncology Group recommend platinum-based systemic chemotherapy in combination with an anti-angiogenic agent such as bevacizumab, however, overall survival remains poor following diagnosis and options for patients who fail chemotherapy are limited. Yttrium-90 (Y90) radioembolization (RE) has shown great promise in the treatment of chemo-refractory colorectal liver metastases. We describe a 30-year-old female with a history of stage IB endocervical adenocarcinoma who later developed metastases to the liver, that were unresponsive to multiple chemotherapeutics and chemoembolization, and was successfully treated with Y90 RE with concurrent systemic Pembrolizumab. The Y90 RE treatment resulted in positive clinical and imaging responses with improvement in her quality of life, all of which continue to persist at the time of writing this manuscript about 8-months into her RE treatment.